These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38243775)

  • 1. Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Marras C; Fereshtehnejad SM; Berg D; Bohnen NI; Dujardin K; Erro R; Espay AJ; Halliday G; Van Hilten JJ; Hu MT; Jeon B; Klein C; Leentjens AFG; Mollenhauer B; Postuma RB; Rodríguez-Violante M; Simuni T; Weintraub D; Lawton M; Mestre TA
    Mov Disord; 2024 Mar; 39(3):462-471. PubMed ID: 38243775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease Subtypes: Critical Appraisal and Recommendations.
    Mestre TA; Fereshtehnejad SM; Berg D; Bohnen NI; Dujardin K; Erro R; Espay AJ; Halliday G; van Hilten JJ; Hu MT; Jeon B; Klein C; Leentjens AFG; Marinus J; Mollenhauer B; Postuma R; Rajalingam R; Rodríguez-Violante M; Simuni T; Surmeier DJ; Weintraub D; McDermott MP; Lawton M; Marras C
    J Parkinsons Dis; 2021; 11(2):395-404. PubMed ID: 33682731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.
    Lawton M; Baig F; Toulson G; Morovat A; Evetts SG; Ben-Shlomo Y; Hu MT
    Mov Disord; 2020 Feb; 35(2):279-287. PubMed ID: 31693246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of Parkinson's Disease Subtypes.
    Marras C; Chaudhuri KR; Titova N; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1366-1377. PubMed ID: 32749651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Espay AJ; Schwarzschild MA; Tanner CM; Fernandez HH; Simon DK; Leverenz JB; Merola A; Chen-Plotkin A; Brundin P; Kauffman MA; Erro R; Kieburtz K; Woo D; Macklin EA; Standaert DG; Lang AE
    Mov Disord; 2017 Mar; 32(3):319-324. PubMed ID: 28233927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    ZhuParris A; Thijssen E; Elzinga WO; Makai-Bölöni S; Kraaij W; Groeneveld GJ; Doll RJ
    Mov Disord; 2023 Oct; 38(10):1795-1805. PubMed ID: 37401265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arguing against the proposed definition changes of PD.
    Boeve BF; Dickson DW; Duda JE; Ferman TJ; Galasko DR; Galvin JE; Goldman JG; Growdon JH; Hurtig HI; Kaufer DI; Kantarci K; Leverenz JB; Lippa CF; Lopez OL; McKeith IG; Singleton AB; Taylor A; Tsuang D; Weintraub D; Zabetian CP
    Mov Disord; 2016 Nov; 31(11):1619-1622. PubMed ID: 27492190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.
    Evers LJW; Krijthe JH; Meinders MJ; Bloem BR; Heskes TM
    Mov Disord; 2019 Oct; 34(10):1480-1487. PubMed ID: 31291488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.
    Berg D; Postuma RB; Bloem B; Chan P; Dubois B; Gasser T; Goetz CG; Halliday GM; Hardy J; Lang AE; Litvan I; Marek K; Obeso J; Oertel W; Olanow CW; Poewe W; Stern M; Deuschl G
    Mov Disord; 2014 Apr; 29(4):454-62. PubMed ID: 24619848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Simonet C; Mahlknecht P; Marini K; Seppi K; Gill A; Bestwick JP; Lees AJ; Giovannoni G; Schrag A; Noyce AJ
    Mov Disord; 2023 Sep; 38(9):1636-1644. PubMed ID: 37317903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Outeiro TF; Alcalay RN; Antonini A; Attems J; Bonifati V; Cardoso F; Chesselet MF; Hardy J; Madeo G; McKeith I; Mollenhauer B; Moore DJ; Rascol O; Schlossmacher MG; Soreq H; Stefanis L; Ferreira JJ
    Mov Disord; 2023 Jul; 38(7):1127-1142. PubMed ID: 37156737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East.
    Khalil H; Chahine LM; Siddiqui J; Salari M; El-Jaafary S; Aldaajani Z; Abu Al-Melh M; Mohammad TM; Abu Snineh M; Syed NA; Bhatt M; Habib MA; Habahbeh M; Tabbal SD; Jeon B; Bajwa JA
    J Parkinsons Dis; 2020; 10(2):729-741. PubMed ID: 32176653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Yassine S; Gschwandtner U; Auffret M; Duprez J; Verin M; Fuhr P; Hassan M
    Mov Disord; 2023 Aug; 38(8):1451-1460. PubMed ID: 37310340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?
    Fereshtehnejad SM; Postuma RB
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):34. PubMed ID: 28324303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Deuschl G; Antonini A; Costa J; Śmiłowska K; Berg D; Corvol JC; Fabbrini G; Ferreira J; Foltynie T; Mir P; Schrag A; Seppi K; Taba P; Ruzicka E; Selikhova M; Henschke N; Villanueva G; Moro E
    Mov Disord; 2022 Jul; 37(7):1360-1374. PubMed ID: 35791767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Disclosure in Prodromal Parkinson's Disease.
    Schaeffer E; Toedt I; Köhler S; Rogge A; Berg D
    Mov Disord; 2021 Dec; 36(12):2833-2839. PubMed ID: 34351002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtypes of Parkinson's disease: state of the field and future directions.
    Marras C
    Curr Opin Neurol; 2015 Aug; 28(4):382-6. PubMed ID: 26110797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.